Intraocular Pressure-Reducing Effects After Treatment is Changed to Cosopt® Monotherapy in Broadly Defined Primary Open-Angle Glaucoma or Ocular Hypertension
Kobayashi Eye Clinic, Sendai
Purpose: We investigated the effectiveness of monotherapy with Cosopt® in reducing intraocular pressure (IOP) in patients who could not tolerate the side effects of prostaglandin (PG) formulations or who preferred to avoid combination therapy.
Subjects and methods: The subjects were patients with broadly defined primary open-angle glaucoma or ocular hypertension who had been treated with PG formulations combined with brinzolamide. Mean IOP was compared before and after treatment was changed to monotherapy with Cosopt®.
Results: Overall, switching to monotherapy with Cosopt® significantly reduced IOP (p=0.038), particularly in the group of patients who had been treated with unoprostone combined with brinzolamide (p=0.005). However, IOP did not change in the subjects who had received PG analogs with the suffix "-prost" combined with brinzolamide.
Conclusions: Our results show that Cosopt® is effective in reducing IOP, and that it can be considered as a treatment option for patients with glaucoma who cannot tolerate the side effects of PG formulations or who are unresponsive to PG.
日医大医会誌 2013; 9(3), 152-155
Cosopt® ophthalmic solution, 0.5% timolol maleate, 1% dorzolamide hydrochloride, β-blocker, prostaglandin
Shigeki Kobayashi, Kobayashi Eye Clinic, 1-28 Showa-machi, Aoba-ku, Sendai-shi, Miyagi 981-0913, Japan